Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
The present study was designed to investigate the effect of montelukast sodium, a leukotriene D(4) receptor antagonist, and 1,2,3,4,tetrahydroisoquinoline, a leukotriene D(4) synthetic pathway inhibitor, on the development of morphine dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Morphine (5 mg/kg, i.p.) was administered twice daily for a period of 5 days following which a single injection of naloxone (8 mg/kg, i.p.) precipitated the opioid withdrawal syndrome in mice. Behavioral observations were made for a period of 30 min immediately after naloxone treatment. The withdrawal syndrome was quantitatively assessed in terms of withdrawal severity score and the frequency of jumping, rearing, fore paw licking and circling. Montelukast sodium as well as 1,2,3,4,tetrahydroisoquinoline, markedly and dose dependently (p<0.01) attenuated the morphine-naloxone-induced opioid withdrawal syndrome in mice. However, administration of montelukast sodium or 1,2,3,4,tetrahydroisoquinoline did not alter the activity of the central nervous system, assessed in terms of locomotor activity count thus ruling out any per se sedative action of montelukast sodium. Further, pretreatment with montelukast sodium or 1,2,3,4,tetrahydroisoquinoline did not alter the acute analgesic effect of morphine. Thus, leukotriene D(4) may be involved in the development of opioid dependence and the precipitation of its withdrawal syndrome and thus may serve as a viable pharmacological target to tackle the problem of opioid addiction.
Rehni
Ashish K
AK
Chitkara College of Pharmacy, Chandigarh-Patiala National Highway, Rajpura-140401, Patiala, Punjab, India. ashishkrehni@gmail.com
Singh
Inderbir
I
Singh
Nirmal
N
Bansal
Nitin
N
Bansal
Seema
S
Kumar
Manoj
M
D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D003521:Cyclopropanes; D005260:Female; D020024:Leukotriene Antagonists / Q000494:pharmacology*; D017998:Leukotriene D4 / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009293:Opioid-Related Disorders / Q000523:psychology*; D010147:Pain Measurement / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000523:psychology*; D013440:Sulfides; D044005:Tetrahydroisoquinolines / Q000494:pharmacology
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D009292:Narcotic Antagonists; D011804:Quinolines; D013440:Sulfides; D044005:Tetrahydroisoquinolines; D009270:Naloxone; C014843:1,2,3,4-tetrahydroisoquinoline; D017998:Leukotriene D4; C093875:montelukast